The Drug-Induced Respiratory Disease Website and App

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.r Airway pigmentation (black, bluish, petechial)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.q Tongue involvement (edema, glossitis, hematoma)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.h Dyspnea, unexplained otherwise

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

V. Pleural and/or pericardial involvement

V.b Eosinophilic pleural effusion

VII. Mediastinal involvement

VII.a Lymphadenopathy (intrathoracic)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.q Tongue involvement (edema, glossitis, hematoma)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.p Disordered breathing during sleep - Sleep apnea

XI. Miscellaneous

XI.r Death following exposure or poisoning

IV. Airway involvement

IV.d Cough (lone)

V. Pleural and/or pericardial involvement

V.b Eosinophilic pleural effusion

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.e Laryngospasm (a.k.a. laryngismus)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.q Tongue involvement (edema, glossitis, hematoma)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.au Visceral angioedema (can cause relapsing abdominal pain)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.d Cough (lone)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.q Tongue involvement (edema, glossitis, hematoma)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.q Tongue involvement (edema, glossitis, hematoma)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.m ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.o Focal/localized area of pneumonitis/fibrosis

I. Interstitial/parenchymal lung disease

I.y Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ad Radiation recall pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.h Major/massive hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.l Alveolar hemorrhage, localized (e.g. lobar)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.c Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

IV. Airway involvement

IV.d Cough (lone)

IV. Airway involvement

IV.j Bronchiolitis (a clinical-imaging pattern suggestive of)

IV. Airway involvement

IV.k Bronchiectasis

IV. Airway involvement

IV.n Obstructive airway dysfunction (see also IVc, XVx)

IV. Airway involvement

IV.t Sptutum production - Bronchorrhea - 'Bronchitis'

IV. Airway involvement

IV.y Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

IV. Airway involvement

IV.ab Exacerbation or deterioration of preexisting COPD

IV. Airway involvement

IV.ac Exacerbation or deterioration of preexisting asthma

IV. Airway involvement

IV.ad Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)

IV. Airway involvement

IV.al Sputum production - Bonchorrhea - ‘Bronchitis’

V. Pleural and/or pericardial involvement

V.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VI. Pulmonary vasculopathy

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

VI. Pulmonary vasculopathy

VI.b Pulmonary arterial hypertension

VII. Mediastinal involvement

VII.a Lymphadenopathy (intrathoracic)

VII. Mediastinal involvement

VII.e Granulomatous mediastinal lymphadenopathy

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.q Tongue involvement (edema, glossitis, hematoma)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.t Vocal cord paresis/paralysis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.r Myasthenia gravis - Myasthenic-like syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.m Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.s Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.ah Granulomatosis with polyangiitis (typically ANCA pos.) - GPA flare

X. Systemic/Distant conditions, syndromes and reactions

X.an Cytokine release syndrome - Cytokine storm

X. Systemic/Distant conditions, syndromes and reactions

X.aw Connective tissue disease

X. Systemic/Distant conditions, syndromes and reactions

X.ax Scleroderma

X. Systemic/Distant conditions, syndromes and reactions

X.ay Polymyalgia rheumatica

X. Systemic/Distant conditions, syndromes and reactions

X.bi Temporal arteritis (Horton’s)

XI. Miscellaneous

XI.d Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

XI. Miscellaneous

XI.n Neutropenia, agranulocytosis (w/wo infection/sepsis)

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.r Heart failure (biventricular, congestive)

XII. Cardiovascular involvement / toxicity

XII.s Heart block (bundle branch- or AV-)

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XV. Pathology

XV.e Path: ILD with a granulomatous component (see also Im)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.x Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XV. Pathology

XV.bb Path: Airway inflammation

XV. Pathology

XV.ca Path: Myocarditis

XV. Pathology

XV.cw Path: Myocardial vasculitis

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.e Imaging: Pulmonary opacities with a subpleural distribution

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.z Imaging: A large nodule or a mass

XVI. Imaging

XVI.ai Imaging: A 'tree-in-bud' pattern

XVII. Infections & related conditions

XVII.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XVII. Infections & related conditions

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XVII. Infections & related conditions

XVII.o Nocardia pulmonary/systemic infection

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.b BAL: An excess proportion of neutrophils

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.m ILD with a granulomatous component

IV. Airway involvement

IV.d Cough (lone)

V. Pleural and/or pericardial involvement

V.b Eosinophilic pleural effusion

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.q Tongue involvement (edema, glossitis, hematoma)

XV. Pathology

XV.e Path: ILD with a granulomatous component (see also Im)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.b Hematoma of/around central airway wall potentially causing UAO

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.q Tongue involvement (edema, glossitis, hematoma)